Citations

Clear

942 citation(s) found for "Shi, Bo".

Abstract C41: Chc1L is a tumor suppressor involved in development of histiocyte-rich neoplasms
Spillane, David, Wang, Ding Yan, Wang, Youdong , Stewart, Keith, Newbigging, Susan, Shi, Chang-Xin , Gramolini, Anthony O. , Liu, Mingyao , Wen, Xiao‐Yan

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 19_Supplement | Pages: C41-C41

10.1158/1538-7445.fbcr13-c41 Get It

Abstract Human chromosome 13q14 is one of the hotspots of chromosomal deletion in prostate cancer, multiple myeloma, and chronic lymphocytic leukemia. Chromosome Condensation 1-like (CHC1L) is an uncharacterized gene in this region. CHC1L is found within the smallest common region of loss of heterozygosity in prostate cancer, and its decreased expression is linked to pathogenesis and progression of both prostate cancer and multiple myeloma. In the present study, we describe the generation and characterization of Chc1L gene knockout mice. Knockout mice develop normally and display an exaggerated proliferative response to LPS stimulation of cultured bone marrow and spleen cells at ten weeks of age. At approximately two years of age, both homozygous and heterozygous mice have markedly increased incidence of tumorigenesis, 80% and 56% respectively, compared to wild-type mice, 26%. The tumors are distributed most commonly to the spleen, mesenteric lymph nodes, liver and small intestine. The morphologic and immunophenotypic features of the tumor cells are consistent with those of tissue histiocytes, and most Chc1L knockout and heterozygote mice succumb to either Histiocytic Sarcoma or Histiocyte-Associated Lymphoma. These data provide the first direct evidence that Chc1L is a tumor suppressor gene involved in suppression of histiocyte-rich neoplasms. Citation Format: David Spillane, Ding Yan Wang, Changxin Shi, Youdong Wang, Anthony Gramolini, Keith Stewart, Susan Newbigging, Mingyao Liu, Xiao-Yan Wen. Chc1L is a tumor suppressor involved in development of histiocyte-rich neoplasms. [abstract]. In: Proceedings of the Third AACR International Conference on Frontiers in Basic Cancer Research; Sep 18-22, 2013; National Harbor, MD. Philadelphia (PA): AACR; Cancer Res 2013;73(19 Suppl):Abstract nr C41.
Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
Haluska, Paul , Menefee, Michael E., Rosenberg, Jonathan, Northfelt, Donald W. , LaVallee, Theresa , Shi, Li , Yu, Xiang‐Qing, Burke, Patricia, Huang, Jaiqi, Viner, Jaye L., McDevitt, Jennifer, LoRusso, Patricia , Menefee, Michael, Northfelt, Donald, Plimack, Elizabeth R. , Rosenberg, Jonathan, Burke, Patricia

Mayo Clinic

Clinical Cancer Research | July 15, 2014 | Volume: 20 | Issue: 18 | Pages: 4747-4757

10.1158/1078-0432.ccr-14-0114 | PMID 25024259 Get It

Abstract Purpose: This phase I, multicenter, open-label, single-arm, dose-escalation, and dose-expansion study evaluated the safety, tolerability, and antitumor activity of MEDI-573 in adults with advanced solid tumors refractory to standard therapy or for which no standard therapy exists. Experimental Design: Patients received MEDI-573 in 1 of 5 cohorts (0.5, 1.5, 5, 10, or 15 mg/kg) dosed weekly or 1 of 2 cohorts (30 or 45 mg/kg) dosed every 3 weeks. Primary end points included the MEDI-573 safety profile, maximum tolerated dose (MTD), and optimal biologic dose (OBD). Secondary end points included MEDI-573 pharmacokinetics (PK), pharmacodynamics, immunogenicity, and antitumor activity. Results: In total, 43 patients (20 with urothelial cancer) received MEDI-573. No dose-limiting toxicities were identified, and only 1 patient experienced hyperglycemia related to treatment. Elevations in levels of insulin and/or growth hormone were not observed. Adverse events observed in >10% of patients included fatigue, anorexia, nausea, diarrhea, and anemia. PK evaluation demonstrated that levels of MEDI-573 increased with dose at all dose levels tested. At doses >5 mg/kg, circulating levels of insulin-like growth factor (IGF)-I and IGFII were fully suppressed. Of 39 patients evaluable for response, none experienced partial or complete response and 13 had stable disease as best response. Conclusions: The MTD of MEDI-573 was not reached. The OBD was 5 mg/kg weekly or 30 or 45 mg/kg every 3 weeks. MEDI-573 showed preliminary antitumor activity in a heavily pretreated population and had a favorable tolerability profile, with no notable perturbations in metabolic homeostasis. Clin Cancer Res; 20(18); 4747–57. ©2014 AACR.
Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study
Shi, Qian , Louvet, Christophe , Everson, Richard B., Kellner, Udo, Clancy, Thomas E. , Pipas, J. Marc , Resnick, Murray B. , Meyers, Michael O. , Wu, Tsung‐Teh, Huntsman, David G. , Validire, Pierre , Farooq, Umar , Pavey, Emily S., Beaudry, Guillaume, Haince, Jean-François, Fradet, Yves , Sargent, Daniel J. , Gill, Sharlene , Farooq, Umar , Shi, Qian , Fradet, Yves

Mayo Clinic

Clinical Cancer Research | June 12, 2014 | Volume: 20 | Issue: 16 | Pages: 4361-4369

10.1158/1078-0432.ccr-13-2659 | PMID 24919572 Get It

Abstract Purpose: Recurrence risk assessment to make treatment decisions for early-stage colon cancer patients is a major unmet medical need. The aim of this retrospective multicenter study was to evaluate the clinical utility of guanylyl cyclase C (GCC) mRNA levels in lymph nodes on colon cancer recurrence. Methods: The proportion of lymph nodes with GCC-positive mRNA (LNR) was evaluated in 463 untreated T3N0 patients, blinded to clinical outcomes. One site's (n = 97) tissue grossing method precluded appropriate lymph node assessment resulting in post hoc exclusion. Cox regression models tested the relationship between GCC and the primary endpoint of time to recurrence. Assay methods, primary analyses, and cut points were all prespecified. Results: Final dataset contained 366 patients, 38 (10%) of whom had recurrence. Presence of four or more GCC-positive lymph nodes was significantly associated with risk of recurrence [hazard ratio (HR) = 2.46, 95% confidence interval (CI), 1.07–5.69, P = 0.035], whereas binary GCC LNR risk class (HR = 1.87, 95% CI, 0.99–3.54, P = 0.054) and mismatch repair (MMR) status (HR = 0.77, 95% CI, 0.36–1.62, P = 0.49) were not. In a secondary analysis using a 3-level GCC LNR risk group classification of high (LNR > 0.20), intermediate (0.10 < LNR ≤ 0.20), and low (LNR ≤ 0.10), high-risk patients had a 2.5 times higher recurrence risk compared with low-risk patients (HR = 2.53, 95% CI, 1.24–5.17, P = 0.011). Conclusions: GCC status is a promising prognostic factor independent of traditional histopathology risk factors in a contemporary population of patients with stage IIa colon cancer not treated with adjuvant therapy, but GCC determination must be performed with methodology adapted to the tissue procurement and fixation technique. Clin Cancer Res; 20(16); 4361–9. ©2014 AACR.
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Zhu, Yuan Xiao , Braggio, Esteban , Shi, Chang-Xin, Kortuem, K. Martin, Bruins, Laura A., Schmidt, Jessica, Chang, Xiu-Bao, Langlais, Paul R. , Luo, Moulun , Jedlowski, Patrick , LaPlant, Betsy, Laumann, Kristina, Bergsagel, P. Leif , Lacy, Martha Q. , Champion, Mia D., Stewart, A. Keith, Bergsagel, P. Leif , Langlais, Paul, Lacy, Martha, Fonseca, Rafaël , Mıkhael, Joseph , Braggio, Esteban

Mayo Clinic

Blood | June 10, 2014 | Volume: 124 | Issue: 4 | Pages: 536-545

10.1182/blood-2014-02-557819 | PMID 24914135 Get It

Key PointsWe identified CRBN-binding proteins and confirmed recent work implicating the Ikaros transcription factors as important members. Low IZKF1 levels predict lack of IMiD responsiveness and shorter OS; IZKF1 expression is a potential predictive biomarker for clinic application.
Hepatic Uterus-Like Mass Misdiagnosed as Hepatic Abscess
Sopha, Sabrina C., Rosado, Flavia, Smith, J. Joshua , Merchant, Nipun B. , Shi, Chanjuan , Rosado, Flavia G N, Smith, J Joshua

Mayo Clinic

International Journal of Surgical Pathology | May 14, 2014 | Volume: 23 | Issue: 2 | Pages: 134-139

10.1177/1066896914534465 | PMID 24827588 Get It

Background. Hepatic endometriosis/uterus-like mass is rare and may be overlooked during hepatic cyst workups. We report a case of uterus-like mass, misdiagnosed as hepatic abscess. Case Report: A 47-year-old woman developed abdominal pain and vomiting. Infectious colitis with hepatic abscess was diagnosed, and remained antibiotic-refractory. Fine-needle aspiration and core biopsies showed benign contents. The patient presented to our institution with symptoms and normal blood work. Laparoscopic excision demonstrated a 1.4-cm cyst composed of endometrial glands (estrogen receptor+ and progesterone receptor+) and stroma (CD10+) with smooth muscle actin (SMA+), arranged in an organoid fashion. The patient, status-post hysterectomy, had no history or symptoms of endometriosis. Conclusion. This rare case illustrates the merit of considering uterus-like mass/endometriosis in the differential diagnosis of antibiotic-refractory hepatic cysts. Cyst heterogeneity may confound needle biopsy. We report the first instance of a hepatic uterus-like mass, with a review of related entities, postulated histogenesis, and important clinical associations.
Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of theKRASGene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial)
Sha, Dan , Shi, Qian , Sargent, Daniel J. , Diasio, Robert B. , Lee, Adam M. , Alberts, Steven R. , Sinicrope, Frank A. , Sargent, Daniel J , Shi, Qian

Mayo Clinic

Clinical Cancer Research | April 12, 2014 | Volume: 20 | Issue: 12 | Pages: 3319-3327

10.1158/1078-0432.ccr-14-0069 | PMID 24727325 Get It

AbstractPurpose: A let-7 microRNA-complementary site (LCS6) polymorphism in the 3′ untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression. We evaluated the LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS) in patients with stage III colon cancer who enrolled in a phase III clinical trial (NCCTG N0147).Experimental Design: The LCS6 genotype was assayed by real-time PCR in DNA extracted from whole blood (n = 2,834) and compared with paired tumor tissue (n = 977). χ2 and two-sample t tests were used to compare baseline factors and KRAS mutation status between patients defined by LCS6 variant status. Log-rank tests and multivariate Cox models assessed associations between LCS6 status and DFS, respectively.Results: We identified 432 (15.2%) blood samples and 143 (14.6%) tumor samples heterozygous or homozygous for the LCS6 G-allele, and 2,402 of 2,834 (84.8%) blood samples and 834 of 977 (85.4%) tumor samples homozygous for the LCS6 T-allele. Genotype results were highly concordant (99.8%) in cases with paired blood and tumor tissue (n = 977). G-allele carriers were significantly more frequent in Caucasians versus other races (χ2 test, P < 0.0001). The LCS6 genotype was not associated with KRAS mutation status, clinicopathologic features (all P > 0.2), or DFS (log-rank P = 0.49; HR, 0.929; 95% confidence interval, 0.76–1.14), even after combining LCS6 genotype with KRAS mutation status.Conclusions: In the largest association study investigating the LCS6 polymorphism in colon cancers, the germline LCS6 genotype was not associated with KRAS mutation status or with clinical outcome in patients with stage III tumors. Clin Cancer Res; 20(12); 3319–27. ©2014 AACR.
Pituitary adenylate cyclase–activating polypeptide is reduced in Alzheimer disease
Han, Pengcheng, Liang, Winnie S. , Baxter, Leslie C. , Yin, Junxiang , Tang, Zhiwei , Beach, Thomas G. , Caselli, Richard J., Reiman, Eric M. , Shi, Jiong , Baxter, Leslie C. , Caselli, Richard J.

Mayo Clinic

Neurology | April 10, 2014 | Volume: 82 | Issue: 19 | Pages: 1724-1728

10.1212/wnl.0000000000000417 | PMID 24719484 Get It

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF –Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Yoon, Harry H. , Tougeron, David , Shi, Qian , Mahoney, Michelle R., Nelson, Garth D. , Nair, Suresh , Thibodeau, Stephen N. , Goldberg, Richard M. , Sargent, Daniel J. , Nair, Suresh G, Alberts, Steven R. , Sinicrope, Frank A. , Sargent, Daniel J , Shi, Qian , Tougeron, David

Mayo Clinic

Clinical Cancer Research | April 1, 2014 | Volume: 20 | Issue: 11 | Pages: 3033-3043

10.1158/1078-0432.ccr-13-3140 | PMID 24687927 Get It

Abstract Purpose: We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF–wild-type tumors, because BRAF mutation was associated with poor prognosis, and BRAF and KRAS mutations are mutually exclusive. Experimental Design: The seven most common KRAS mutations in codon 12 and codon 13 were examined in 2,478 BRAF–wild-type tumors. Because KRAS mutations in codon 12 (n = 779) or 13 (n = 220) were not predictive of adjuvant cetuximab benefit, study arms were pooled for analysis. Disease-free survival (DFS) was evaluated by HRs using Cox models. Results: KRAS mutations in codon 12 (multivariate HR, 1.52; 95% confidence interval, CI, 1.28–1.80; P < 0.0001) or codon 13 (multivariate HR, 1.36; 95% CI, 1.04–1.77; P = 0.0248) were significantly associated with shorter DFS compared with patients with wild-type KRAS/BRAF tumors, independent of covariates. KRAS codon 12 mutations were independently associated with proficient mismatch repair (P < 0.0001), proximal tumor site (P < 0.0001), low grade, age, and sex, whereas codon 13 mutations were associated with proximal site (P < 0.0001). Conclusion: KRAS mutations in either codon 12 or 13 are associated with inferior survival in patients with resected stage III colon cancer. These data highlight the importance of accurate molecular characterization and the significant role of KRAS mutations in both codons in the progression of this malignancy in the adjuvant setting. Clin Cancer Res; 20(11); 3033–43. ©2014 AACR.
Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia
He, Bai‐Liang , Shi, Xiangguo , Man, Cheuk Him , C.H., Alvin, Ekker, Stephen C. , Chow, Howard C.H., So, Chi Wai Eric , Choi, William W.L., Leung, Anskar Y.H. , Zhang, Wenqing , Zhang, Yiyue , Alvin, C. H. , Ekker, Stephen C

Mayo Clinic

Blood | March 4, 2014 | Volume: 123 | Issue: 16 | Pages: 2518-2529

10.1182/blood-2013-02-486688 | PMID 24591202 Get It

Key Points Zebrafish flt3 plays an important role in the initiation of definitive hematopoietic stem cells. Expression of human FLT3-ITD activates endogenous flt3 signaling and induces myeloid expansion.
Feasibility of using 3D MR elastography to determine pancreatic stiffness in healthy volunteers
Shi, Yu , Glaser, Kevin J. , Venkatesh, Sudhakar K. , Ben‐Abraham, Ephraim I., Ehman, Richard L. , Venkatesh, Sudhakar K , Shi, Yu

Mayo Clinic

Journal of Magnetic Resonance Imaging | February 5, 2014 | Volume: 41 | Issue: 2 | Pages: 369-375

10.1002/jmri.24572 | PMID 24497052 Get It

Purpose To evaluate the feasibility of using three‐dimensional (3D) MR elastography (MRE) to determine the stiffness of the pancreas in healthy volunteers. Materials and Methods Twenty healthy volunteers underwent 1.5 Tesla MRE exams using an accelerated echo planar imaging (EPI) pulse sequence with low‐frequency vibrations (40 and 60 Hz). Stiffness was calculated with a 3D direct inversion algorithm. The mean shear stiffness in five pancreatic subregions (uncinate, head, neck, body, and tail) and the corresponding liver stiffness were calculated. The intrasubject coefficient of variation (CV) was calculated as a measure of the reproducibility for each volunteer. Results The mean shear stiffness (average of values obtained in different pancreatic subregions) was (1.15 ± 0.17) kPa at 40 Hz, and (2.09 ± 0.33) kPa at 60 Hz. The corresponding liver stiffness was higher than the pancreas stiffness at 40 Hz ([1.60 ± 0.21] kPa, mean pancreas‐to‐liver stiffness ratio: 0.72), but similar at 60Hz ([2.12 ± 0.23) kPa, mean ratio: 0.95). The mean intrasubject CV for each pancreatic subregion was lower at 40 Hz than 60 Hz ( P < 0.05 for all subregions, range: 11.9–15.7% at 40 Hz and 16.5–19.6% at 60 Hz). Conclusion The 3D pancreatic MRE can provide promising and reproducible stiffness measurements throughout the pancreas, with more consistent data acquired at 40 Hz. J. Magn. Reson. Imaging 2015;41:369–375. © 2013 Wiley Periodicals, Inc .